Literature DB >> 26179199

The growing problem of benign connective tissue tumours.

David M Thomas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26179199     DOI： 10.1016/S1470-2045(15)00147-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial.

Authors:  Shenglong Li; Peng Chen; Qiankun Yang
Journal:  J Bone Oncol       Date:  2019-01-23       Impact factor: 4.072

2.  The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS).

Authors:  Heather L Gelhorn; Xin Ye; Rebecca M Speck; Sandra Tong; John H Healey; Susan V Bukata; Richard D Lackman; Lindsey Murray; Grant Maclaine; William R Lenderking; Henry H Hsu; Paul S Lin; William D Tap
Journal:  J Patient Rep Outcomes       Date:  2019-02-04

3.  Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial.

Authors:  Jiaji Yue; Wei Sun; Shenglong Li
Journal:  J Bone Oncol       Date:  2022-06-24       Impact factor: 4.491

4.  Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.

Authors:  Heather L Gelhorn; Sandra Tong; Kelly McQuarrie; Christina Vernon; Jennifer Hanlon; Grant Maclaine; William Lenderking; Xin Ye; Rebecca M Speck; Richard D Lackman; Susan V Bukata; John H Healey; Vicki L Keedy; Stephen P Anthony; Andrew J Wagner; Daniel D Von Hoff; Arun S Singh; Carlos R Becerra; Henry H Hsu; Paul S Lin; William D Tap
Journal:  Clin Ther       Date:  2016-04-01       Impact factor: 3.393
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.